Drug intelligence / Profile preview

Lead Clusterin Molecule

Development stage: Preclinical
Lead developer: FloBiotech
Modality: Recombinant Proteins and Enzymes
Administration: Peripheral, Intraarterial, Intraperitoneal, Intrathecal

Overview

FloBiotech's lead therapeutic candidate is a clusterin-based molecule designed to treat Alzheimer's disease and other neurodegenerative conditions. It specifically targets patients with the CLU rs11136000 risk genotype, which is associated with reduced levels of secreted clusterin (sCLU). The drug aims to restore extracellular proteostasis and enhance synaptic resilience, thereby mitigating tau-mediated neurodegeneration. Currently in the preclinical stage, this program leverages the company's FloCells platform to address tau-driven pathology and restore synaptic function.

Other names: sCLUClusterin programClusterin (sCLU) lead molecule

Targets

CLU (Clusterin)

Beyond the preview

Go deeper on Lead Clusterin Molecule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lead Clusterin Molecule.

Explore the full profile